The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial
Délégation Paris 5 · Inserm · +3 more institutions
Abstract
BACKGROUND: Phase I clinical studies have demonstrated the feasibility of implanting autologous skeletal myoblasts in postinfarction scars. However, they have failed to determine whether this procedure was functionally effective and arrhythmogenic. METHODS AND RESULTS: This multicenter, randomized, placebo-controlled, double-blind study included patients with left ventricular (LV) dysfunction (ejection fraction
Citation impact
- FWCI
- 93.44
- Percentile
- 100%
- References
- 39
Authors
15- PMPhilippe MenaschéCorresponding
Délégation Paris 5, Inserm, Universität Hamburg, Université Paris Cité, University Medical Center Hamburg-Eppendorf
- OAOttavio Alfieri
Délégation Paris 5, Inserm, Universität Hamburg, Université Paris Cité, University Medical Center Hamburg-Eppendorf
- SJStefan Janssens
Délégation Paris 5, Inserm, Universität Hamburg, Université Paris Cité, University Medical Center Hamburg-Eppendorf
- WJWilliam J. McKenna
Délégation Paris 5, Inserm, Universität Hamburg, Université Paris Cité, University Medical Center Hamburg-Eppendorf
- HRHermann Reichenspurner
Délégation Paris 5, Inserm, Universität Hamburg, Université Paris Cité, University Medical Center Hamburg-Eppendorf
Topics & keywords
- Medicine
- Ejection fraction
- Placebo
- Cardiology
- Internal medicine
- Interquartile range
- Myocardial infarction
- Adverse effect
- Good health and well-being